Remittive effects of intramuscular alefacept in psoriasis.

Kenneth B Gordon*, Richard G. Langley

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


Alefacept is the first biologic agent approved for the treatment of chronic plaque psoriasis in the United States. Alefacept, administered intravenously (i.v.) or intramuscularly (i.m.), was found to be well tolerated, safe, and efficacious in two pivotal phase 3 studies in patients with moderate to severe psoriasis. Treatment with i.v. alefacept was associated with a median duration of off-treatment response of 216 days (approximately 7 months). In a follow-up extension study to the phase 3 i.m. study, duration of therapeutic response was also examined. Patients who achieved a > or = 75% reduction in baseline Psoriasis Area and Severity Index (PASI 75) with the first course of alefacept 15 mg i.m. in the phase 3 study maintained a PASI 50 for a median duration of 209 days. In addition, the extension study demonstrated that a second course of i.m. alefacept is safe and well tolerated in patients with psoriasis.

Original languageEnglish (US)
Pages (from-to)624-628
Number of pages5
JournalJournal of drugs in dermatology : JDD
Issue number6
StatePublished - Jan 1 2003

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Remittive effects of intramuscular alefacept in psoriasis.'. Together they form a unique fingerprint.

Cite this